Lantheus Holdings (LNTH) | Stock Overview & Key Data
Lantheus Holdings Performance Comparison
Stock Range
Today's Range
Low: $52.33
High: $53.97
on October 3, 2025
52 Week Range
Low: $47.25
High: $118.21
on August 6, 2025
on November 4, 2024
All-Time High: $126.89 on July 15, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$3.7B
EPS
3.76
P/E Ratio (TTM)
14.32
Forward P/E
7.77
P/B Ratio
3.14
PEG Ratio
0.49
Div. Yield
N/A
ROE
24.71%
Beta
0.091
Debt to Equity
52.75
Financial Highlights
Profitability
Gross Margin
63.75%
Operating Margin
23.27%
Profit Margin
17.82%
Returns and Earnings
Return on Assets (TTM)
13.34%
Return on Equity (TTM)
24.71%
EBITDA
$537.9M
Net Income (TTM)
$271.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$22.22
Quarterly Revenue Growth (YoY)
-4.10%
Quarterly Earnings Growth (YoY)
26.90%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Lantheus Holdings LNTH | 3.66B Mid-cap | 6.36% | -2.39% | -33.06% | -44.63% | -39.38% | -49.50% | -17.74% | 301.12% |
| Zoetis ZTS | 65.09B Large-cap | -1.63% | -7.29% | -7.89% | -11.87% | -11.75% | -26.34% | -3.23% | -12.26% |
| Haleon Plc - ADR HLN | 41.44B Large-cap | 1.47% | -9.50% | -12.68% | -14.35% | -5.19% | -13.69% | 46.96% | 20.78% |
| Regencell Bioscience RGC | 8.46B Mid-cap | 13.25% | 23.73% | -25.62% | 2,571.88% | 13,053.85% | 15,445.45% | 1,960.24% | 6,007.14% |
| Alkermes plc ALKS | 5.26B Mid-cap | 11.37% | 3.53% | 7.66% | -1.90% | 8.03% | 7.21% | 40.35% | 84.22% |
| Prestige Consumer PBH | 3.79B Mid-cap | 1.57% | -4.41% | -20.03% | -24.35% | -17.70% | -7.08% | 28.56% | 72.12% |
Ownership & Short Interest
Insider Ownership
2.24%
Institutional Ownership
116.76%
Shares Short
7M
Short Ratio
4.84
Short % of Shares Outstanding
14.49%
Average 10-Day Volume
2M
Average 90-Day Volume
1M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is LNTH's 52-week high and low?
- In the last 52 weeks, Lantheus Holdings reached a high of $118.21 (on November 4, 2024) and a low of $47.25 (on August 6, 2025).
- What is the market cap and P/E ratio for LNTH?
- Curious about Lantheus Holdings's size and valuation? Its market capitalization stands at 3.66B. When it comes to valuation, the P/E ratio (trailing twelve months) is 14.32, and the forward P/E (looking ahead) is 7.77.
- Does LNTH pay dividends? If so, what's the yield?
- As for dividends, Lantheus Holdings isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Lantheus Holdings's main competitors or similar companies to consider before investing?
When looking at Lantheus Holdings, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS65.09B Healthcare Drug Manufacturers - Specialty & Generic -26.34% -3.23% Haleon Plc - ADR
HLN41.44B Healthcare Drug Manufacturers - Specialty & Generic -13.69% 46.96% Regencell Bioscience
RGC8.46B Healthcare Drug Manufacturers - Specialty & Generic 15,445.45% 1,960.24% Alkermes plc
ALKS5.26B Healthcare Drug Manufacturers - Specialty & Generic 7.21% 40.35% Prestige Consumer
PBH3.79B Healthcare Drug Manufacturers - Specialty & Generic -7.08% 28.56% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Lantheus Holdings Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Lantheus Holdings's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 24.71%, the Debt to Equity ratio from the most recent quarter is 52.75, and its Gross Profit Margin stands at 63.75%.
- What is the recent revenue and earnings growth for LNTH?
- Looking at Lantheus Holdings's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by -4.10%, and quarterly earnings saw a YoY growth of 26.90%.
- How much of LNTH stock is held by insiders and institutions?
- Wondering who owns Lantheus Holdings stock? Company insiders (like executives and directors) hold about 2.24% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 116.76%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.